Adeno-associated virus (AAV) is a promising vector for human gene therapy due to its low immunogenicity and pathogenicity. AAV vectors are constructed by replacing the AAV rep and cap genes with a therapeutic gene cassette. The vector is delivered along with a helper plasmid providing rep and cap functions. Several preclinical and clinical studies have demonstrated the potential of AAV vectors for treating lung cancer, liver cancer, diabetes, and HIV/AIDS by delivering genes such as P130, E1a, Acrp30, and 2,5-dkgr. Further research is still needed but AAV shows promise as a safe and effective method for human gene therapy.